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Mesenchymal stem cells (MSC) are a widely used population in cell therapy for their ability to diﬀerentiate into distinct tissues and
more lately, for their immunomodulatory properties. However, the use of heterogeneous populations could be responsible for the
nondesired outcomes reﬂected in the literature. Here, we analyse the diﬀerent capacities of ﬁve one-cell-derivedMSC clones to exert
their immunomodulation ex vivo. We assessed proliferation assays in cocultures of MSC clones and puriﬁed cluster of
diﬀerentiation (CD)3+, CD4+, or CD8+ lymphocytes; analysed the regulatory T (Treg) cells fold change rate; determined the
eﬀects on viability of peripheral blood mononuclear cells (PBMC); and also measured the coculture cytokine proﬁles (Th1/Th2).
Conditioned media (CM) of diﬀerent clones were also used to perform both proliferation assays and to analyse Treg fold
change. The ﬁve clones analysed in this work were able to generate heterogeneous environments. Diﬀerent clones inhibited
proliferation of CD3+ and CD4+ lymphocytes, with diﬀerent intensities. Surprisingly, all clones promoted proliferation of CD8+
lymphocytes. Diﬀerent MSC clones and their CM were able to increase the number of Treg with diﬀerent intensities. Finally,
diﬀerent clones also promoted diﬀerent eﬀects on the viability of PBMC treated with ultraviolet light. Considering all these data
together, it seems that diﬀerent clones, even from the same donor, can promote a wide spectrum of responses from anti-
inﬂammatory to proinﬂammatory character. This fact may be important to standardise the design of personalized cell therapy
protocols, thus diminishing the aforementioned undesired outcomes existing nowadays in this type of therapies.
1. Introduction
Mesenchymal stem cells (MSC) are stem cells that can be
isolated from tissues of adult organisms. They were discov-
ered by Friedenstein et al. [1–3] in the late 70’s in the bone
marrow of mice and guinea pigs, and since then, they have
been isolated from numerous tissues, such as the umbilical
cord [4], dental pulp [5], and adipose tissue [6, 7], among
many others. These MSC are a cell type with great potential
for cell therapy, as well as for the treatment of autoim-
mune/autoinﬂammatory diseases [8]. This potential lies in
the possibility of isolating them from the adult organism,
diminishing their ethical implications; in their ability to dif-
ferentiate into osteogenic [9], adipogenic [10], and chondro-
genic [11] lineages; in the possibility to be transdiﬀerentiated
into other cell types, such as neurons [12]; in their medium-
low expression of major histocompatibility complex (MHC)
class I and MHC class II [13], which allows their use in
allogeneic therapies [14], and ﬁnally, in their immunomodu-
latory properties, which promote, among other responses, an
inhibition of most immune cell types function [15], as well as
an increase in the number and activity of regulatory T cells
(Treg) [16].
The mechanisms by which MSCs exert their immuno-
modulatory eﬀects involve a multitude of soluble factors
[17] and cell-to-cell contact [18], although the degree of con-
tribution of each of these factors in such immunomodulation
remains a matter of debate nowadays. Moreover, this immu-
nomodulation has been studied mostly on total PBMCs, with
only a few studies carried out on speciﬁc lymphocyte
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populations, such as CD3, CD4, or CD8 lymphocytes. In
addition, the heterogeneity of MSC [19], their multiple ori-
gins, the diﬀerences in isolation methods, and the absence
of a single marker that allows us to correctly identify them,
may be ultimately responsible for the wide range of published
outcomes [20, 21].
In our previous work [22], we used clonal populations of
MSC, derived from adipose tissue, previously isolated using
cloning rings [23], in order to homogenize the population
as much as possible. In that work, we demonstrated the dif-
ferent capacities of MSC clones to exert immunosuppression
on total PBMC populations; secrete diﬀerent cytokines with
or without stimulation; and show diﬀerent intensities and
percentages of expression of the markers generally used to
identify them, like cluster of diﬀerentiation (CD)44, CD73,
CD90, and CD105, and diﬀerent gene methylation proﬁles
related to cytokine signalling of each one of the clones.
In this work, we delve deeper into the study of these
clones, analysing their eﬀect on puriﬁed populations of
T lymphocytes, the cytokine environment resulting from
cocultivation with PBMC, the ability of clones to modify
the Treg population, the eﬀect of CM on PBMC and Treg
proliferation, and ﬁnally, the eﬀect of these clones on the
viability of PBMC exposed to proapoptotic stimuli.
2. Materials and Methods
2.1. Cells and Reagents. All procedures involving human cells
were approved by the University of Alicante Ethics Commit-
tee. PBMC were obtained by centrifugation in the density
gradient in Ficoll-Hypaque (GE Healthcare, Chalfont, St
Giles, UK) from the antecubital vein of 57 healthy volunteers.
Total T lymphocytes, as well as T helper (Th) and T cytotoxic
(Tc) cell subpopulations, were puriﬁed by incubating the
PBMC with the RosetteSep Human T Cell Enrichment
Cocktail, RosetteSep Human CD4+ T Cell Enrichment
Cocktail, and RosetteSep Human CD8+ T Cell Enrichment
Cocktail (StemCell Technologies, Vancouver, BC, Canada),
respectively, prior to gradient density centrifugation with
Ficoll-Hypaque. For PBMC culture, complete RPMI (Roswell
ParkMemorial Institute)mediawas used to growPBMC, con-
sisting in RPMI (Hyclone, Logan, UT, USA) supplemented
with 10% fetal bovine serum (FBS) (Biowest, Nuaillé, France),
1% penicillin/streptomycin (Biowest, Nuaillé, France), and
1% glutamine (Biowest, Nuaillé, France).
Clones were isolated from heterogeneous MSC popula-
tions derived from liposuction of two healthy volunteers, as
previously described [23], three of them from one individual
(clones 1.10, 1.22, and 1.7) and two of them from the other
one (clones 3.10 and 3.5). Brieﬂy, heterogeneous MSC popu-
lations were cultivated in plates at very low conﬂuence to
identify individual cells in complete cloning medium
[HAM F-12 (Gibco, Carlsbad, CA, USA) supplemented with
20% FBS, 100U/mL penicillin, 100μg/mL streptomycin, and
15mM HEPES (Gibco, Carlsbad, CA, USA)] until deﬁned
colonies (30–50 cells) were formed. Once the colonies were
identiﬁed, they were isolated using cloning rings to limit their
conﬂuence. Then, the clones were detached using trypsin
0.05% with ethylenediaminetetraacetic acid (EDTA) 0.02%
(Gibco, Paisley, UK) and transferred to new culture ﬂasks
in complete Dulbecco’s Modiﬁed Eagle’s Medium (DMEM),
consisting in DMEM 25mM glucose (Gibco, Paisley, UK),
supplemented with 10% FBS, 1% penicillin/streptomycin,
and 1% glutamine. Membrane antigen expressions (CD44,
CD73, CD90, and CD105) were conﬁrmed by ﬂow cytometry
[22]. All the clones used in this work were between passages
6–10 for proliferation assays, 10–12 for cytokine’s proﬁles,
11–14 for Treg analysis, and 12–15 for the viability assay.
MSC clones were grown in complete DMEM. Media were
renewed twice a week until cell conﬂuence was reached.
Afterwards, media were washed twice with phosphate-
buﬀered saline (PBS) (Hyclone, Logan, UT, USA), and cells
were detached from the ﬂask with trypsin to carry out the dif-
ferent experiments or to make further passages in order to
continue expanding.
Monoclonal antibodies for CD4, CD25, and Forkhead
Box P3 (FoxP3) antigens for ﬂow cytometry were purchased
from eBioscience (San Diego, CA, USA) and CD11b from
Becton Dickinson (San Diego, CA, USA). Fixation/perme-
ability solution for intranuclear staining of FoxP3 staining
was purchased from eBioscience (San Diego, CA, USA).
Carboxyﬂuorescein succinimidyl ester (CFSE) and phytohae-
magglutinin (PHA) were purchased from Sigma-Aldrich
(Saint-Quentin Fallavier, France) and propidium iodide from
Fisher Scientiﬁc (Leicestershire, UK).
2.2. MSC Conditioned Media. To obtain MSC conditioned
media (CM), MSC clones were tripsinized and seeded in a
25 cm2 ﬂask (TPP, Trasadingen, Switzerland) at the rate of
105 cells per ﬂask, in 4mL of complete DMEM. After 96
hours of culture, supernatants were collected and centrifuged
at 360g for 5 minutes. Then, they were frozen at −20°C until
their usage.
2.3. Analysis of Cytokines inMSC-PBMCCocultures.Cytokine
analysis in coculture supernatants was performed by seeding
105 PBMC in 96 ﬂat-bottom well plates (TPP, Trasadingen,
Switzerland), with and without the diﬀerent MSC clones at
1 : 10 ratio (MSC : PBMC), in complete RPMI medium for 96
hours. They were stimulated with 10μg/mL of PHA, and no
stimulation condition was used as control. Supernatants were
then collected, centrifuged at 360g, and frozen at −20°C until
analysis. Cytokine detectionwas performed byﬂow cytometry
(FacsCanto II, Becton Dickinson, San Diego, CA, USA) and
the Human Th1/Th2/Th9/Th17/Th22 13plex FlowCytomix
Multiplex kit from eBioscience (San Diego, CA, USA). The
analysed cytokines were interleukin- (IL-) 1β, tumour necro-
sis factor- (TNF-) α, IL-10, interferon- (IFN-) γ, IL-4, IL-2,
IL-22, IL-13, IL-17A, IL-9, IL-5, and IL-12p70. Data were
analysed using FlowCytomix Pro Software (eBioscience,
San Diego, CA, USA).
2.4. CFSE Labelling. To analyse cell proliferation, prior to
culture, PBMC and puriﬁed CD3+, CD4+, or CD8+ lympho-
cytes were labelled with CFSE at a ﬁnal concentration of
5μM, for 5min at room temperature, according to Parish
and Warren [24].
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2.5. Proliferation Assay. To analyse the eﬀect of MSC-CM on
PBMC proliferation, 105 cells were cultured in 96 ﬂat-bottom
well plates in a ﬁnal volume of 200μL consisting in 100μL of
complete RPMI with 100μL of every MSC-CM. 100μL of
complete DMEM was used as the control. To analyse the
eﬀect of MSC clones on proliferation of puriﬁed CD3+,
CD4+, and CD8+ lymphocyte subsets, 105 lymphocytes were
cultured with MSC clones (ratio MSC : PBMC, 1 : 10) in 96
well plates in a ﬁnal volume of 200μL of complete RPMI.
All the cultures were stimulated with 10μg/mL of PHA.
Nonstimuli condition was used as the control in all cases.
After ﬁve days of culture, cells were collected, and prolifera-
tion was measured by ﬂow cytometry (EPICS-XL, Beckman
Coulter, Brea, CA).
2.6. Treg Analysis. Analysis of the eﬀect of MSC on the Treg
cells was performed by seeding 105 PBMC with the diﬀerent
MSC clones at an MSC : PBMC ratio (1:10) in 200μL
complete RPMI medium, on 96-well ﬂat-bottom plates. The
condition without MSC was used as the control. Similarly,
the eﬀect ofMSC-CMwas also analysed by seeding 105 PBMC
in 100μL of complete RPMI media and 100μL of CM from
each one of the clones. Complete DMEM was used as the
negative control. After three days of culture, the cells were
recovered and stained with monoclonal antibodies against
the membrane antigens CD4 and CD25, as well as the intra-
nuclear transcription factor FoxP3. Cells were processed by
ﬂow cytometry (EPICS-XL, Beckman Coulter, Brea, CA).
2.7. Viability Assay. To assess the eﬀect of MSC clones on
PBMC survival, 105 PBMC were cocultured with clones
1.10 and 3.5 (ratio MSC : PBMC, 1 : 20), in a 96-well ﬂat-
bottom plate, at a ﬁnal volume of 200μL of complete RPMI.
After 6 days of coculture, cells were moved to a new 96-well
ﬂat-bottom plate and then irradiated with ultraviolet (UV)
light through a transilluminator for 30 seconds. Twenty-
four hours later, they were stained with propidium iodide
(10μg/mL) and analysed by ﬂow cytometry (EPICS-XL,
Coulter). Condition without UV stimulation was used as a
basal mortality control.
2.8. Statistics. Descriptive statistics and statistical inference
were performed using the GraphPad Prism (GraphPad, La
Jolla, CA, USA) software statistical analysis package. In all
cases, the results were checked for normality by the
Kolmogorov-Smirnov test. Later, Student’s t-test for two sets
of data was used to analyse signiﬁcant diﬀerences between
the diﬀerent growing conditions. F test of the analysis of
variance (ANOVA) was used to analyse clones among
themselves, or between themselves and the control condition.
Post hoc analysis was performed with Fisher’s least signiﬁ-
cant diﬀerence (LSD) method.
3. Results
3.1. Th1/Th2/Th17 Proﬁle in MSC Clones-PBMC Cocultures
3.1.1. IL-1β. Under nonstimulatory conditions (Table 1), the
presence of MSC clones resulted in an increase in IL-1β
levels. This increase was statistically signiﬁcant for all clones,
with no diﬀerences between them, except for pair 1.7 and
1.22, with the higher and the lower increase, respectively.
PHA stimulation (Table 2) led to an increase in this cytokine
in all cases, being statistically signiﬁcant for clones 1.7 and
3.10. The rest of clones did not substantially modify IL-1β
levels with respect to the condition of absence of MSC clones.
3.1.2. IL-2. This cytokine showed a variable behaviour. Its
expression was either absent or very low (close to 50 pg/mL).
Although no signiﬁcant diﬀerences were found between the
diﬀerent growing conditions or between clones, it could be
observed that, in the presence of clones in the culture, there
was generally less cytokine production, both with (Table 2)
or without PHA (Table 1). There was an undetectable
amount of cytokine in the cases of clones 1.10, 1.7, and 3.5
(in the absence of stimuli) and 3.5 and 3.10 (in the presence
of stimuli).
Table 1: Cytokine concentrations (pg/mL) in unstimulated cocultures of MSC clones with PBMCs (mean± SD).
Concentration of cytokines (pg/mL) in PBMC :MSC cocultures
w/o MSC 1.10 1.22 1.7 3.10 3.5
IL-1β 253.6 (248.7)a 996.2 (434.1)bc 788.0 (490.8)b 1133.6 (689.8)c 1071.4 (440.5)bc 919.4 (425.1)bc
TNF-α 106.4 (72.5)a 14.6 (12.8)b 7.3 (6.7)b 29.0 (9.5)ab 18.4 (10.4)b 5.5 (9.6)b
IL-10 2.1 (3.6) 129.8 (35.3) 148.6 (76.8) 150.7 (109.7) 128.6 (95.1) 161.7 (89.0)
IFN-γ 3.9 (6.7) — — 45.7 (79.1) 59.5 (72.5) —
IL-4 3.6 (6.2) — 3.6 (6.2) — 7.2 (12.4) —
IL-2 30.6 (52.9) — 32.9 (57.0) — 16.9 (29.2) —
IL-22 — 18.0 (31.1) — — — —
IL-13 — 10.9 (18.9) — — — —
IL-17A — — — — 3.8 (6.6) —
IL-9 1.0 (1.7) — — — — —
IL-5 — — — — — —
IL-12p70 — — — — — —
Groups (n = 3) containing the same letters are not statistically diﬀerent for ANOVA (LSD), p < 0 05.
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3.1.3. IL-12p70.Only the presence of clone 1.7 and with PHA
stimulation (Table 2) led to detection of this cytokine at a
very low concentration (about 40 pg/mL).
3.1.4. IL-17A.No cytokine was detected in any of the growing
conditions without stimuli (Table 1). However, in the pres-
ence of PHA (Table 2), moderate levels of IL-17 were
detected in the supernatants of PBMC alone. This amount
doubled in the presence of the MSC clones, except for clone
1.10, which showed a contrary trend to the other ones, since
the concentration of this cytokine decreased signiﬁcantly.
3.1.5. IL-22. In the absence of stimulus (Table 1), only very
low levels of IL-22 (about 50 pg/mL) were detected in the
presence of clone 1.10. However, PHA stimulation
(Table 2) was associated with low-moderate levels of this
cytokine in PBMC alone (about 150 pg/mL). This amount
decreased to a lesser or greater extent depending on the
MSC clone present in the culture and even became undetect-
able in the case of clones 1.10 and 3.5, with only signiﬁcant
diﬀerences between both clones and clone 3.10.
3.1.6. TNF-α. All MSC clones caused a very marked decrease
in this cytokine, both in the absence (Table 1) and the pres-
ence of mitogen. Stimulation with PHA (Table 2) leads this
cytokine to a signiﬁcant increase in the absence of MSC
clones. The clone 1.7 was the one with the lowest capacity
to decrease levels of this cytokine and showed signiﬁcant
diﬀerences with the rest of clones.
3.1.7. IFN-γ. Without MSC clones, this cytokine increased
signiﬁcantly after adding PHA (Table 2) to the culture. How-
ever, this increase was practically suppressed in the presence
of clones 1.10, 1.22, and 3.5, which also showed signiﬁcant
diﬀerences with clones 1.7 and 3.10, which seemed to have
no eﬀect on IFN-γ synthesis and secretion. Interestingly,
these last two clones were able to promote IFN-γ production
in the absence of stimulus (Table 1).
3.1.8. IL-4. Cytokine levels were nearly undetectable in the
diﬀerent growing conditions, reaching maximum values of
20 pg/mL. Without stimuli (Table 1) and only in the presence
of clone 3.10, a slight increase in cytokine levels could
be observed.
3.1.9. IL-5. This cytokine was not detected in the absence of
stimulus (Table 1). However, stimulation of PBMC with
PHA (Table 2) resulted in an increase around 170pg/mL in
all cases, which was signiﬁcantly lower in the presence of
MSC clones. Signiﬁcant diﬀerences were found between
clones 1.10 and 3.10, which respectively caused the greatest
and the least reduction.
3.1.10. IL-9. This cytokine was only detected in some condi-
tions under PHA stimulation (Table 2), reaching peak levels
of around 500pg/mL, which was signiﬁcantly lower in the
presence of diﬀerent clones of MSC.
3.1.11. IL-10. There was a clear trend towards an increase in
this cytokine when PBMC were cocultured with MSC clones
without stimuli (Table 1). PHA produced an increase in this
cytokine (Table 2), which was lower with MSC clones vs.
PBMC alone, except for the case of clone 1.7. This decrease
was signiﬁcant for clones 1.10 and 3.10.
3.1.12. IL-13. In the absence of stimuli (Table 1), this cytokine
was only detected at very low levels in the presence of clone
1.10. PHA stimulation (Table 2) increased this cytokine in
the absence of MSC clones and, in a lesser degree, in the pres-
ence of clones, and not even being produced in the case of
cultures containing clones 1.10 and 3.5, which showed signif-
icant diﬀerences with clone 3.10. However, these diﬀerences
were signiﬁcant for all clones vs. PBMC alone.
3.2. Proliferation Assays
3.2.1. CD3+ Puriﬁed Lymphocytes and MSC Cocultures.MSC
clones did not induce proliferation of CD3+ T lymphocytes in
Table 2: Cytokine concentrations (pg/mL) in phytohemagglutinin-stimulated (10 μg/mL) cocultures of MSC clones with PBMCs
(mean± SD).
Concentration of cytokines (pg/mL) in PBMC :MSC cocultures
w/o MSC 1.10 1.22 1.7 3.10 3.5
IL-1β 2055.1 (151.5)a 2344.6 (247.9)a 2025.1 (498.3)a 2809.0 (662.8)b 2770.9 (712.0)b 2136.7 (740.2)a
TNF-α 416.8 (23.5)a 32.4 (7.2)c 42.5 (26.6)c 208.6 (101.8)b 79.9 (29.7)c 14.1 (24.4)c
IL-10 819.4 (433.2)a 352.2 (62.4)b 531.8 (190.3)bc 783.1 (312.2)ac 455.0 (45.3)b 531.4 (148.0)bc
IFN-γ 2512.4 (1829.8)a 359.9 (252.7)b 270.3 (207.2)b 3180.4 (1441.5)a 2093.2 (1854.4)a 186.1 (177.3)b
IL-4 1.9 (3.3) — — — — —
IL-2 27.8 (31.6) 18.9 (32.8) 18.9 (32.8) 22.5 (39.0) — —
IL-22 51.53 (77.31)ab —a 12.5 (21.7)ab 40.7 (70.5)ab 81.3 (71.0)b —a
IL-13 998.0 (246.7)a —b 110.7 (96.7)bc 123.2 (108.4)bc 210.6 (325.7)c —b
IL-17A 549.3 (330.5)ab 350.1 (90.4)a 936.2 (508.1)cd 906.6 (613.8)cd 723.3 (307.0)bc 1017.5 (403.0)d
IL-9 527.3 (126.4)a —b 20.2 (20.6)b 119.3 (117.2)c 45.7 (73.9)bc 2.9 (2.6)b
IL-5 168.2 (120.8)a 10.3 (17.9)b 58.5 (50.8)bc 63.9 (50.4)bc 83.4 (110.2)c 31.4 (54.4)bc
IL-12p70 — — — 37.4 (22.8) — —
Groups (n = 3) containing the same letters are not statistically diﬀerent for ANOVA (LSD), p < 0 05.
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the absence of stimuli (data not shown). In the presence of
PHA, MSC clones promoted a strong inhibition of prolifera-
tion, clones 1.10 and 3.5 being the most suppressive ones
(Figure 1(a)). Interclonal analysis showed small signiﬁcant
diﬀerences of clones 1.10 and 3.5 vs. clone 3.10.
3.2.2. CD4+ Puriﬁed Lymphocytes and MSC Cocultures.
Under no stimulation conditions, a signiﬁcant increase in
proliferation of puriﬁed CD4+ lymphocytes was detected
in the presence of all MSC clones vs. control (Figure 2(a))
but not between clones. However, in the presence of stimu-
lus, cocultures showed a signiﬁcant decrease in proliferation
(Figure 1(b)), being clones 1.7 and 1.10 the least and the
most inhibitors, respectively. Finally, interclonal analysis
showed signiﬁcant diﬀerences of clone 1.7 vs. clones 1.10
and 1.22. The same than before, diﬀerences were also found
between clones 1.10 and 3.10.
3.2.3. CD8+ Puriﬁed Lymphocytes and MSC Cocultures. The
presence of MSC clones produced a signiﬁcant increase in
CD8+ lymphocyte proliferation (Figure 2(b)). Interclonal
analysis showed values close to statistical signiﬁcance
between clones 1.10–1.7, 1.10–3.10, 1.7–3.5, and 3.10–3.5.
In the absence of MSC, PHA caused a slight increase in the
size of part of the puriﬁed CD8+ lymphocytes (Figure 3).
However, MSC caused a clear increase in the proliferation
of this population (Figure 1(c)), showing variable degrees of
signiﬁcance for clones 1.10 (p = 0 0304), 1.22 (p = 0 0339),
1.7 (p = 0 0105), 3.10 (p = 0 0062), and 3.5 (p = 0 0241).
Interclonal analysis showed that clone 3.10 promoted the
highest level of proliferation when compared to the rest of
clones. Clone 1.7 also showed diﬀerences with clones 1.10
and 3.5, resulting in an intermediate level of proliferation.
Integrin CD11b was analysed for proliferated CD8+ lympho-
cytes in cocultures with clones 1.10 and 3.5, resulting in a
clear majority of CD11b− population (Figure 4).
3.2.4. PBMC andMSC-CM Cultures. In the absence of stimu-
lus, no signiﬁcant diﬀerenceswere found in lymphocytes’ pro-
liferation between the diﬀerent MSC-CM and control. In the
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Figure 1: Lymphocyte proliferation in PHA-stimulated (10 μg/mL) cultures in the presence or absence of diﬀerent mesenchymal stem cell
(MSC) clones. Ratio: MSC : lymphocytes (1 : 10). (a) Coculture of MSC-CD3+ puriﬁed cells (n ≥ 3). (b) Coculture of MSC-CD4+ puriﬁed
cells (n = 4). (c) Coculture of MSC-CD8+ puriﬁed cells (n = 8). (d) Culture of PMBC and conditioned media of diﬀerent MSC clones
(n = 9). Results expressed as median (SD). p values obtained by ANOVA (LSD test). Means containing equal letters are not signiﬁcant to
each other (p < 0 05).
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presence of PHA (Figure 1(d)), all CM slightly decreased
lymphocyte proliferation vs. control, reaching signiﬁcant
diﬀerences for clones 1.10 (p = 0 0198) and 1.22 (p < 0 0001).
Interclonal analysis did not show signiﬁcant diﬀerences.
3.3. Treg Analysis. The fold change of Treg cells
(CD4+CD25+FoxP3+) increased when PBMC were cocul-
tured with MSC clones [1.10 (p = 0 0247), 1.22 (p = 0 0052),
1.7 (p = 0 0095), 3.10 (p = 0 0216), and 3.5 (p = 0 0131)]
(Figure 5(a)). Numerous diﬀerences were observed in the
interclonal comparison, being clones 1.22 and 1.7 which
promoted the highest changes.
All the CM also caused an increase in the expression of
Treg (Figure 5(b)), although signiﬁcant diﬀerences were only
found in the case of clone 1.7-CM. However, the p values for
the rest of CM vs. control indicate a strong tendency to
increase Treg (between 0.0635 and 0.1444). No interclonal
diﬀerences were found.
3.4. Viability Assay. Viability analysis of PBMC showed sig-
niﬁcant diﬀerences between UV light treatment and negative
control for all growing conditions. In the absence of UV light,
the clones did not exert any inﬂuence on the viability of
PBMC. However, in UV-treated cells, the presence of clone
1.10 signiﬁcantly decreased PBMC mortality (p = 0 0020),
contrary to clone 3.5, which slightly increased it (p = 0 0225)
(Figure 6), resulting in a signiﬁcant diﬀerence between the
two clones (p = 0 0006).
3.5. Comparative Analysis of MSC Clones. The set of data
obtained in this study shows that the diﬀerent MSC clones
present a wide range of behaviours that goes from anti-
inﬂammatory to proinﬂammatory. This allows us to charac-
terize the diﬀerent clones according to diﬀerent factors, such
as cytokine proﬁle, inhibition of diﬀerent lymphocyte popu-
lations, modulation of Treg cells, and the eﬀect on viability
(Figure 7).
4. Discussion
Apart from the multiple applications that MSC may have
in regenerative medicine, one of the most important prop-
erties of these cells is that they are able to interact with
diﬀerent cell populations of the immune system. Although
the mechanisms by which MSC exert immunomodulation
are not yet fully characterized, we know that they are
highly heterogeneous [25].
When MSC are cultured as colonies derived from a sin-
gle cell, each clone shows a variable degree of plasticity [26].
This could be related to the diﬀerent isolation protocols, the
growing conditions and/or the number of passages, because
certain clones with proliferative advantages could replace the
rest. In addition, some studies have shown that the source of
the MSC also compromises their diﬀerentiation towards one
or more lineages [26, 27]. According to our previous studies,
the clones analysed in this work present heterogeneity in
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Figure 2: Lymphocyte proliferation nonstimulated cultures in the presence or absence of diﬀerent mesenchymal stem cell (MSC) clones.
Ratio: MSC : lymphocytes (1 : 10). (a) Coculture of MSC-CD4+ puriﬁed cells (n = 4). (b) Coculture of MSC-CD8+ puriﬁed cells (n = 8).
Results expressed as median (SD). p values obtained by ANOVA (LSD test). Means containing equal letters are not signiﬁcant to each
other (p < 0 05).
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showing proliferation versus cell size. Ratio: MSC : lymphocytes
(1 : 10). The height of the histogram is proportional to the number
of cells. Top, without stimulus and with MSC; left, without stimulus
and without MSC; right, with stimulus and with MSC; bottom, with
stimulus and without MSC. Histogram representative of one of
nine cocultures.
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their diﬀerentiation potential towards osteogenic and adipo-
genic lineages [23] and also in their membrane phenotype,
cytokine proﬁles, and in their capacity to inhibit PBMC’s
proliferation [22].
In the present study, when clones of MSC are in coculture
with PBMC, increases and decreases in both proinﬂamma-
tory (Th1) and anti-inﬂammatory (Th2) cytokines were also
detected. Without stimulation, all cocultures showed a signif-
icant increase of IL-1β and IL-10 and a signiﬁcant decrease of
TNF-α. However, IL-1β increased between 3 and 5 times and
IL-10 between 65 and 75 times, depending on the clone, thus
supporting the well-known immunosuppressive character of
MSC. Clone 1.7 is related to the greater increase of IL-1β and
the smaller decrease of TNF-α, opposite to clone 1.22.
Regarding the rest of the cytokines, IL-2 and IL-4 were not
detected in the presence of clones 1.10, 1.7, and 3.5. Only in
the presence of clone 1.10, IL-22 and IL-13 were detected,
while IFN-γ was only present for clones 1.7 and 3.10. PHA
caused a general increase of the diﬀerent cytokines, although
in a diﬀerent way to that observed in the absence of stimuli.
All clones promoted an increase of IL-17A, except for clone
1.10. In the case of TNF-α, all clones behaved the same than
in the absence of stimuli, although more intensely. All clones
also resulted in a decrease of anti-inﬂammatory cytokines,
being clones 1.7 and 3.10 the ones promoting the lowest
inhibition. At the same time, these clones were related with
the highest levels of several proinﬂammatory cytokines such
as IL-1β, IL-22, and IFN-γ. Taking into account all the
aforementioned data, they could be considered as the most
proinﬂammatory clones. For the rest of the clones, the
opposite was true. As a summary of the cytokines analysis,
clones of diﬀerent individuals may behave similarly, while
clones of the same individual may behave diﬀerently.
Theoretically, we could ﬁnd in every person a wide range of
clones with slightly diﬀerent proﬁles, ranging from a proin-
ﬂammatory to an immunosuppressive phenotype.
MSC can inhibit proliferation of cell populations of
the immune system, without being inherently immunogenic
[28], supporting their allogenic and even xenogeneic,
therapeutic use. Results are, however, incongruent [29] and
might lie in theMSCheterogeneity [27]. In this study, we have
analysed the immunomodulatory capacity of MSC clones to
inhibit the proliferation of lymphocyte subpopulations.
MSC clones did not induce cell proliferation of cocultured
unstimulated puriﬁedCD3+T lymphocytes. However, a slight
proliferation was detected in cocultures with puriﬁed CD4+
and CD8+ lymphocytes. This fact would probably be condi-
tioned by the ﬁnal cytokine environments, resulting from
the diﬀerent interactions between leukocyte populations pres-
ent in the culture in every case. Under stimulatory conditions,
clones 1.10 and 3.5 were two times more eﬀective suppressors
than the other clones. PHA stimulated cocultures showed an
increase in puriﬁed CD8+ lymphocyte proliferation. As far
as we know, this is the ﬁrst study reﬂecting this amazing
behaviour, as it is contrary to what has been previously
described in the literature [30], although it should be noted
that to our knowledge, there are very few studies that have
determined the eﬀect of MSC on this puriﬁed lymphocyte
population, through proliferation assays. It has to be
remarked that PHA stimulation promoted a very low level
of proliferation without MSC. However, the observed eﬀects
on cell size would indicate that certain activation occurred
but being insuﬃcient to translate into proliferation. This
could be determined by the absence of factors derived from
other leukocyte populations, such as Th cells, present in the
rest of the analysed cocultures. By adding MSC to the culture,
clones could provide or promote secretion of these deﬁcient
factors. This is consistent with other authors, which argue that
inhibition of cell proliferationwould bemainly determined by
its stimulating eﬀect on Treg lymphocytes [30, 31]. Interest-
ingly, again diﬀerent patterns between clones are observed.
In fact, clones 1.7 and 3.10 behave similarly to each other,
exhibiting the highest degree of proliferation of CD8+
lymphocytes. The opposite was true for clones 1.10, 1.22,
and 3.5. We decided to measure the degree of expression of
the CD11b membrane antigen on CD8+ proliferating cells.
The proliferating population was essentially CD11b−, having
these CD8+CD11b− lymphocytes been associated with immu-
nosuppressive properties [32], indicating again that MSC
would mainly be exerting their eﬀect by aﬀecting a regulatory
subpopulation, as previously mentioned for Treg cells.
Finally, we have also analysed the eﬀect of CM obtained from
the diﬀerent clones on PBMC proliferation inhibition, being
lower than the one observed under the presence of clones
and only reaching a signiﬁcant value for clone 1.22.
In general terms, the above-mentioned eﬀects on
lymphocyte proliferation inhibition would conﬁrm once
again the diﬀerences between clones when exerting their
immunomodulatory abilities therefore showing how impor-
tant could be a previous characterization of these clones
when using cell-therapy protocols. The diﬀerent eﬀects
observed on Tc lymphocytes proliferation would further
justify this characterization.
We also analysed the eﬀect of MSC clones and its CM on
Treg population. Clone 1.22 caused the highest increase of
Treg, showing this clone and its CM the greatest capacity to
inhibit lymphocyte proliferation as well as high levels of
IL-2, this latter needed for Treg development [33]. However,
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IL-2 was not detected for clones 1.10 and 3.5, thus explaining
the lower observed Treg number. Nevertheless, clone 1.7 pro-
moted similar Treg fold changes than clone 1.22 but did not
promote IL-2 secretion. This fact could be determined by the
presence of other soluble factors such as TGF-β, also impor-
tant for Treg development (not measured in this study).
Interestingly, fold change of FoxP3 induced by clones repro-
duces the same pattern as the one obtained for the analysis of
IL-10, this latter being a characteristic cytokine of Treg.
These results seem to be again in line with studies suggesting
that inhibition promoted by MSC would be mainly mediated
through an indirect eﬀect on Treg cells. CM produced the
same eﬀect as MSC but with a lower intensity. Only clone
1.7 showed a statistically signiﬁcant eﬀect on the Treg’s
exchange rate, reﬂecting again variability between clones.
This is consistent with our data obtained on lymphocyte pro-
liferation, and although support that MSC in the culture
seem to be necessary to get maximum immunomodulatory
eﬀects. CM could also be an option that moreover would
avoid the additional complications often happening when
using cells for therapy.
Several studies have determined the capacity of MSC and
their CM to increase cell viability rescuing apoptotic cells
[32, 33] and to induce apoptosis in tumour cells, encouraging
fact for cell therapy [34]. In this study, we have analysed the
eﬀect of clones 1.10 and 3.5 on the viability of PBMC. Clone
1.10 was able to signiﬁcantly reduce cell mortality, while
clone 3.5 had just the opposite eﬀect. Given that UV is an
apoptotic activator, it is reasonable to think that our clones
would be modifying apoptotic routes. So far, most of the
results of the current study showed similar behaviours for
all clones, diﬀering only in their intensity. However, these
latest results show that heterogeneity of MSC could be also
favouring antagonistic responses. These facts could be caus-
ing unknown unpredictable side eﬀects on the viability of
other cell populations involved in the pathology being treated
and might inﬂuence the ﬁnal clinical results.
In addition, when the eﬀect of clones was analysed from
the perspective of diﬀerences between individuals (by group-
ing clones 1 and 3 separately), we did not ﬁnd signiﬁcant
diﬀerences between them (data not shown). This absence
of diﬀerences supports the possibility of getting a wide
range of clones with distinct behaviours from each patient
that could be used in therapy according to the particular
needings in each case. However, when using heterogeneous
MSCs populations, these speciﬁc behaviours of clones could
be masked.
5. Conclusions
In summary, all the aforementioned results show how impor-
tant can be a previous characterization ofMSC for cell therapy
protocols. This characterization should be approached from
diﬀerent perspectives, not only by looking for the ability of
these cells to diﬀerentiate into diﬀerent tissues, but also by
analysing their immunomodulatory abilities that would result
from the combination of the multiple eﬀects exerted by these
cells. Cell therapy protocols using a clone or a combination
of clones rather than the usual heterogeneous populations
would facilitate their reproducibility and therefore would
allow a better prediction of the pursued eﬀects, also preventing
the usual problems derived from the cellular heterogeneity
applied to diﬀerent individuals. From our point of view, many
of the therapies that are not obtaining the expected results
could have diﬀerent outcomes if their design was approached
from the perspective of the clones or their CM, depending on
whether they wanted to obtain a longer or more speciﬁc eﬀect,
according to what was observed in our ex vivo results and also
in concordance with what was described by other authors [35].
In fact, we could design ex vivo the most appropriate person-
alized therapy in each case, depending not only on the pathol-
ogy to be treated, the duration of the desired eﬀect, and its
degree of activity but also on the individual who will receive
it. According to our results, this design could be done based
on the diﬀerent capacities of these clones to activate or inhibit
a given leukocyte population, to promote a certain balance of
anti- or proinﬂammatory cytokines or a speciﬁc Th17/Treg
balance, or even tomodify the viability of speciﬁc cellular pop-
ulations. As a conclusion, the heterogeneity of MSC, far from
being a handicap for cell therapy, could be used to get more
optimized designed protocols by using clones instead of whole
cell populations.
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